Provention Bio’s $2.9B Acquisition – A Strategic Fit For Sanofi
Sanofi SA (NASDAQ:SNY) has agreed to acquire Provention Bio Inc (NASDAQ:PRVB) for $25.00 per share in cash, representing an equity value of approximately…
Seagen’s $43B Deal To Double Pfizer’s Early-Stage Oncology Pipeline, Seagen Says Is Right Step
Pfizer Inc (NYSE:PFE) has agreed to acquire Seagen Inc (NASDAQ:SGEN) for $229 in cash per Seagen share for a total enterprise value…
Barron’s Top Weekend Stock Picks: Salesforce, Roblox, Dell and A Stock Taking A Big Hit Over SVB Collapse
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
Benzinga Bulls And Bears: Amazon, Meta, Tesla, And A Bitcoin Bull Says Dogecoin Should Be Worthless
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
The Bull And Bear Case For Apple: Expert Analysis
Needham & Co on Friday issued a company update to investors discussing its Bull and Bear cases for Apple Inc (NASDAQ: AAPL).
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
Stocks React To February Jobs Report: The Winners And Losers
The markets have offered investors a rollercoaster ride this week, with a flurry of activity and developments that have sent shockwaves through various sectors.
FDA Casts Doubts Over Roche’s Polivy Label Expansion For Untreated Lymphoma Setting
Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…
AstraZenceca’s Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement…
AstraZeneca’s Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
In a trial, lung cancer patients treated with AstraZeneca plc’s (NASDAQ:AZN) immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the…